Biognosys is excited to attend ASMS 2021 with a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut breakfast seminars. After such a long time without live events, our team is more than thrilled to welcome you to booth #224.

We are proud to announce the upcoming launch of our next-generation Plasma Biomarker Discovery solution, featuring a Launch Webinar on November 9th and Launch Exhibition at SITC 2021 on November 12-14th. The new and improved service will offer unprecedented depth and quantitative precision. The workflow will search the complete plasma proteome to identify up to 3,000 of the most relevant proteins.

Biognosys and Evotec have entered a unique collaboration. It combines Evotec’s partnered drug discovery, development business model, focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transform drug discovery and development.

Much of today’s drug development research relies on genomics and transcriptomics. But these tools are missing a major part of the biological puzzle: the proteome. Our CBO Kristina Beeler shares her thoughts about how proteomics is revolutionizing life science research and why Biognosys is the right partner to accelerate the drug development journey!

Reliable biomarkers are key to develop targeted drugs and make precision medicine a reality. Is proteomics the answer to accelerate the development and commercialization of companion diagnostics? Discover more on how proteomics supports the development of precision medicine in our latest blog article.